Ann: Fluence Operational Update Regarding COVID-19, page-18

Great work N1.

I was wondering about the announcement mentioning:
“Our factory in Changzhou, Jiangsu Province, is continuously producing MABR products and shipping to customers within China and around the world without any material supply chain or shipping delays.”

If “continuously” means 3 shifts running, I would estimate that would be enough to supply making 6 x L4 Aspirals A day. Assuming $70k per L4 unit at 35% margin, we should be generating $147k per working day in gross profit in the China operation.

Hope the adoption of MABR is fast enough to keep the Changzhou plant running 3 shifts it should make us EBITDA positive or even profitable for the year. Niroboxes and other operating units will provide the cream.